P
ARKINSON DISEASE (PD) IS A slowly progressive movement disorder based on the degeneration of nigrostriatal dopaminergic neurons. Highly variable progression rates between individual patients with PD were demonstrated repeatedly in clinical and postmortem pathological studies, leading to uncertainty about the dynamics of cell death before symptom onset.
1,2 The long-latency hypothesis of dopamine cell degeneration in PD implies nigral damage early in life and a subsequent decline of intact dopaminergic neurons with normal aging. 3 In contrast, later onset of dopamine cell loss closer to the manifestation of the disease with an initially high and afterward decreasing rate of nigral cell death over time favors early neuroprotective therapy strategies, which aim to decelerate or stop disease progression.
To provide further insight into this controversy, we present data on the long-term progression of striatal dopaminergic impairment in PD by means of serial fluorodopa F 18 ([ 
METHODS

STUDY SUBJECTS AND CLINICAL MEASUREMENTS
We investigated a total of 31 patients with PD with a wide range of symptom duration and severity at the time of study inclusion ( Table 1) and 16 healthy controls free of neurologic dis-
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eases and medication with central nervous system action (10 men and 6 women; mean±SD age, 54±12 years). Parkinson disease was diagnosed according to the UK brain bank criteria. 4 Disease severity was assessed by the Unified Parkinson's Disease Rating Scale(UPDRS) 5 and the Hoehn and Yahr scale. 6 At follow-up, patients were subdivided into clinical PD subtypes according to the degree to which resting and action tremor items accounted for the total UPDRS stage 3 score: tremor dominant (tremor items accounted for Ͼ75% of the total UPDRS stage 3 score ; n=4), equivalence (25%-75%; n=15), and akinetic-rigid type (Ͻ25%; n=12). Patients with PD were treated with antiparkinsonian medication in various combinations. The study protocol was approved by the local ethics committee, and all study subjects gave their written informed consent to participate in the study.
PET DATA ACQUISITION
The PET scans were performed with 1 of 2 scanners (ECAT EXACT HR or ECAT EXACT; Siemens CTI, Knoxville, Tenn) according to previously described standard procedures. [7] [8] [9] In each patient, one baseline scan and one follow-up scan were undertaken on the same PET camera with a mean ± SD interval of 64.5 ± 22.6 months ( Table 1 ). All antiparkinsonian medication was withdrawn at least 12 hours before PET imaging.
PET DATA ANALYSIS
Data analysis was performed on workstations (SUN Sparc 2; Sun Microsystems, Santa Clara, Calif ). For each subject, both PET scans were exactly coaligned with standard software (MPITool; Advanced Tomovision, Erftstadt, Germany) 10 and analyzed at the same time according to a standardized protocol by one rater (R.H.) blinded for the presence of baseline or follow-up PET scans. In striatal regions of interest, [ 18 F]fluorodopa influx constants (K i = min −1 ) were calculated as described previously 9, 11 according to the graphical Patlak and Blasberg analysis approach.
12
CALCULATION OF DISEASE PROGRESSION AND PRECLINICAL PERIOD
Within each region of interest, the annual decline of [ 
STATISTICS
All analyses were performed with the statistical software package SPSS 10 fluorodopa PET studies to demonstrate a 30% neuroprotective effect of a putative agent. We assumed that patients with PD were included in a parallel group-designed trial either 1 or 10 years after symptom onset with a PET follow-up of either 1 or 5 years. We further assumed that a therapy under investigation would protect patients from 30% of this progression. Data variance was measured by means of the standard deviations of individual predicted changes after 1 and 5 years.
RESULTS
The mean [ Table 2 ). All mean striatal K i values decreased significantly during the scan-to-scan interval ( Table 2 ). In line with a negative exponential decline of [ Annual baseline progression rates, as calculated by logarithmic transformation, are given in Table 3 . Patients with tremor-dominant PD had significantly lower progression rates in the ipsilateral caudate nucleus than those with the equivalence PD subtype (0.6%± 1.9% vs 5.8% ± 3.7%; P = .02). However, putaminal progression rates were not significantly different between clinical PD subtypes ( Table 3 ). The duration of the preclinical disease period was 5.6±3.2 years, with symptom onset at a putamen K i threshold of 69% from controls (Figure 2) . In line with a negative exponential decline of putaminal dopaminergic capacity over time, power analysis showed that the required sample size to demonstrate a significant neuroprotective effect by means of [
18 F]fluorodopa PET strongly decreases with the length of the follow-up period and increases with the patients' symptom duration at the time of study inclusion ( Table 4) .
COMMENT
This study demonstrates a striatal annual PD disease progression ranging from 4.0% to 6.6% of the baseline regional [
18 F]fluorodopa uptake. These data are comparable with those from the largest PET progression study in PD published so far, by Morrish et al, 13 who found an annual baseline PD progression of 8.9% for the putamen and 3.5% for the caudate with the use of the same graphical Patlak and Blasberg plot approach. Moreover, we detected a significantly lower caudate disease progression in tremor-dominant PD, which is in agreement with the often-reported clinical impression of a slower deterioration of disease severity and widely preserved cognitive functions in these patients. 6, 14, 15 It is also in line with a previous anatomic study demonstrating a lower nigral neuronal density in akinetic-rigid compared with tremor-dominant patients. 16 In our PET series, a relatively large patient sample with a wide range of symptom duration and severity was investigated during a follow-up period longer than that reported in many other imaging studies on PD progression. Moreover, we used the sensitive K i analysis approach for determination of disease progression. Presumably, these favorable conditions allowed us to describe significant determinants of PD progression that had not yet been observed in previous PET studies, namely a decrease of progression rates with symptom duration and an increase with the number of available intact dopamine nerve terminals within the putamen. Therefore, we propose a negative exponential loss of dopaminergic cells over time in line with previous anatomic, 1 biochemical, 17 and functional imaging studies using single-photon emission computed tomography with iodine 123-labeled ␤-carboxymethyoxy-3-␤-(4-iodophenyl) tropane (␤-CIT). 18 In this context, confounding pharmacologic effects of antiparkinsonian drugs on imaging progression data have to be considered. To avoid a systematic bias, we stopped medication at least 12 hours before each PET scan, although no significant short-term effects of levodopa and dopamine agonists on radiotracer binding have been demonstrated in previous [ 18 F]fluorodopa PET and dopamine transporter single-photon emission computed tomographic studies. 19, 20 However, a long-term acceleration or slowing of disease progression by dopaminergic drugs cannot be ruled out. Therefore, this question will be the subject of a future study in our PD cohort.
Previous studies estimated the duration of the presymptomatic period in PD to vary from 4.7 to 50 years. 1, 21, 22 Our data suggest that early PD disease progression is not linear but exponentially negative and that the preclinical disease period lasts approximately 6 years with a loss Therefore, our data contradict the long-latency hypothesis of PD proposed by Calne and Langston, 3 which assumes damage to nigral dopaminergic neurons early in life and symptom manifestation after a preclinical period lasting longer than 10 years. In contrast, our PET data showing a constant exponential decline of [ 18 F]fluorodopa uptake suggest an active devastating disease process different from age-related dopaminergic degeneration, which steadily afflicts the present dopaminergic capacity and leads to a relatively short preclinical disease period.
Finally, our findings suggest that agents with presumed neuroprotective properties should be capable of exerting their maximum clinical efficacy in early disease stages. Recent single-photon emission computed tomographic and PET imaging studies proved a significantly slower disease progression in patients with PD treated with the new nonergot dopamine agonists pramipexole and ropinirole hydrochloride, compared with levodopa monotherapy. [23] [24] [25] With respect to the future planning and design of such studies, the power analysis of our data clearly shows that clinical protection trials using [ 18 F]fluorodopa PET as a progression surrogate marker require lower sample sizes and are more promising to achieve significant results if they are initiated as early as possible in the course of the disease.
CONCLUSIONS
The neurodegenerative process in PD seems to follow a negative exponential course and slows down with increasing symptom duration. The nonlinear kinetics of degeneration provide the important rationale for research efforts that are directed at modification of disease progression. Moreover, our results suggest that neuroprotection studies with PET imaging as a surrogate marker should be performed preferably at an early stage of PD. 
